Open AccessTreatment of catastrophic antiphospholipid syndrome to pregnant woman
Author(s) -
N.V. Tytarenko,
І.Л. Кукуруза,
Olga Zasadn?uk,
А.V. Vozniuk,
Andriy Kostyuchenko
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6n1.4524
Subject(s) - eculizumab , catastrophic antiphospholipid syndrome , thrombotic microangiopathy , medicine , rituximab , antiphospholipid syndrome , pregnancy , cyclophosphamide , complication , microangiopathic hemolytic anemia , pediatrics , immunology , thrombotic thrombocytopenic purpura , antibody , chemotherapy , platelet , disease , complement system , biology , genetics
The research aimed to study and analyze the life-threatening complication of antiphospholipid syndrome by acute thrombotic microangiopathy, which can lead to multiorgan damage. The progression of catastrophic antiphospholipid syndrome during pregnancy creates a lot of problems in diagnostic due to its extended clinical manifestations and coincidence with additional obstetric intricacies and microangiopathic diseases. Early diagnosis and aggressive treatment (anticoagulants, glucocorticoids, and plasma metabolism (or intravenous immunoglobulins) remain key factors for favorable. In cases of refractory CAPS, cyclophosphamide or monoclonal antibodies (rituximab, eculizumab) should be considered.